leadf
logo-loader
viewTetra Bio-Pharma

Tetra Bio-Pharma green lit by the FDA to proceed to a Phase 1 clinical study with coronavirus drug

Tetra Bio-Pharma Inc.(TSXV:TBP) (OTCQB:TBPMF) CEO Guy Chamberland tells Proactive the Ottawa-based biotechnology company has received positive feedback from the FDA on its investigational drug called ARDS-003, aiming to treat the coronavirus.

Chamberland says the group will soon initiate a Phase 1 clinical study.

What's more, Chamberland says the biotech has receives conditional approval to graduate to the TSX from the TSX-V.

Quick facts: Tetra Bio-Pharma

Price: - -

TSX-V:TBP
Market: TSX-V
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Tetra Bio-Pharma reveals promising results in inflammatory lung injury...

Tetra Bio-Pharma Inc.(TSX: TBP) (OTCQB: TBPMF) CEO Guy Chamberland tells Proactive the biotechnology company it has revealed promising results of an experimental study with its investigational new drug ARDS-003 in a model of lung injury. Chamberland says the group will soon be submitting the...

1 day, 10 hours ago

2 min read